The Priority Review

Tag

Sofetabart mipitecan

1 story

  1. Clinical trials

    Lilly reports 79% response rate for Sofe-M in platinum-sensitive ovarian cancer

    The Phase 1 study of sofetabart mipitecan (Sofe-M) plus bevacizumab in 29 patients with measurable disease reported a confirmed objective response rate of 79.3% (23/29) and a disease control rate of 100%. The most common grade ≥3 adverse events were neutropenia (42%) and anemia (24%), with 6% of patients discontinuing treatment due to an adverse event.